Pharmaceuticals

Carbapenem-Based Antibiotics Market Performance and Future Outlook at 5.7% CAGR Through 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the carbapenem-based antibiotics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Carbapenem-Based Antibiotics Industry By 2029?

The carbapenem-based antibiotics market size has shown consistent growth in recent years. It is projected to increase from $4.6 billion in 2024 to $4.78 billion in 2025, at a compound annual growth rate (CAGR) of 3.8%. The expansion observed in the historic period is attributable to epidemics and pandemics, the rising prevalence of chronic diseases, advancements in healthcare infrastructure, swift urbanization, and occurrences of natural disasters and health emergencies.

The carbapenem-based antibiotics market is projected to experience robust expansion over the coming years, with its size anticipated to reach $5.97 billion by 2029, achieving a compound annual growth rate (CAGR) of 5.7%. This growth during the forecast period can be attributed to factors such as an increased incidence of hospital-acquired infections, the emergence of multi-drug resistant strains, a growing aging population, a rise in surgical procedures, the proliferation of infectious diseases, and changing demographics. Major trends expected in the forecast period include enhanced supply chain resilience and security, the development of alternative treatments, a shift towards outpatient settings, growing awareness of antimicrobial stewardship, and precision medicine approaches.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

What Major Drivers Are Impacting The Carbapenem-Based Antibiotics Market?

A rise in bacterial infections is projected to drive the expansion of the carbapenem-based antibiotics market moving ahead. These infections are triggered by bacteria, tiny organisms capable of entering the body and leading to various illnesses and manifestations. Carbapenem-based antibiotics are utilized for addressing severe or drug-resistant bacterial infections, encompassing those stemming from both gram-positive and gram-negative bacteria. To illustrate, a report from the US government agency, the Centers for Disease Control and Prevention, in July 2024, indicated that in 2023, 78% of all bacterial infections within the historical catchment area were identified using CIDTs, with 46% exclusively diagnosed via CIDTs. Consequently, the heightened occurrence of bacterial infections fuels the growth of the carbapenem-based antibiotics market.

Which Segment Categories Are Driving Maximum Growth In The Carbapenem-Based Antibiotics Market?

The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types

2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use

2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy

3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections

4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections

5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

Which Long-Term Trends Will Play A Crucial Role In The Carbapenem-Based Antibiotics Market?

A prominent trend emerging in the carbapenem-based antibiotics market is product innovation. Leading companies within the carbapenem-based antibiotics market are actively innovating products to sustain their market position. For instance, in August 2024, the National Health Service, a UK-based Government department, introduced a pioneering subscription scheme for antibiotics in collaboration with the pharmaceutical sector, aimed at combating antimicrobial resistance (AMR). Unveiled on August 12, 2024, this innovative model enables drugmakers to receive fixed annual fees, up to £20 million per drug, irrespective of the volume prescribed, thereby eliminating incentives for overuse. The scheme is valued at approximately £1.9 billion over 16 years and seeks to encourage the development of new antibiotics by ensuring financial viability for pharmaceutical companies. This initiative follows a successful pilot phase and integrates into the UK’s broader strategy to address AMR, which poses a significant global health threat, potentially leading to millions of deaths by 2050 if left unaddressed. The NHS will prioritize products targeting critical pathogens identified by the World Health Organization, reinforcing its commitment to responsible antibiotic stewardship while simultaneously fostering innovation in antibiotic development.

Who Are The Dominant Players In The Carbapenem-Based Antibiotics Market Today?

Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Which Region Is At The Forefront Of Innovation In The Carbapenem-Based Antibiotics Market?

North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp

Browse Through More Reports Similar to the Global Carbapenem-Based Antibiotics Market 2025, By The Business Research Company

Motor Vehicle And Parts Dealers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/motor-vehicle-and-parts-dealers-global-market-report

Automobiles And Heavy Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/automobiles-and-heavy-equipment-global-market-report

Electric Motor And Generator Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/electric-motor-and-generator-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795